[Clinical evaluation of ciclobendazole (C-C 2481) in the treatment of colonic helminth diseases].

Abstract

A total of 105 patients with mild helminthiases have been treated with ciclobendazole, a benzimidazole derivative related to mebendazole. The treatment lasted 3 days. A group of 74 patients received 200 mg/day ciclobendazole while another 31 patients were given double this dose. The excretion rates achieved were very high at 84.2 and 83.3% respectively in trichuriasis and 93.3 and 100% respectively in ascariasis. In a relatively small number of cases of ankylostomiasis, the values were, however, considerable lower (38.5 and 20.0% respectively). Since ciclobendazole is well tolerated, there is a need for studies with higher dosages and possibly also long-term studies.

• Authors: A Degrémont, E Stahel
• Journal: Schweizerische medizinische Wochenschrift (Schweiz Med Wochenschr) Vol. 108 Issue 37 Pg. 1430-3 (Sep 16 1978) ISSN: 0036-7672 [Print] Switzerland
• Vernacular Title: Klinische Bewertung von Ciclobendazol (C-C 2481) bei der Behandlung von Wurmerkrankungen des Darmes.
• PMID: 705298 (Publication Type: English Abstract, Journal Article)

Chemical References

• Benzimidazoles

Topics

• Adult
• Benzimidazoles (therapeutic use)
• Child
• Child, Preschool
• Colonic Diseases (drug therapy)
• Dose-Response Relationship, Drug
• Drug Evaluation
• Feces (parasitology)
• Female
• Helminthiasis (drug therapy)
• Humans
• Male
• Parasite Egg Count